



SOCIETÀ ITALIANA
DI VIROLOGIA

ITALIAN SOCIETY
FOR VIROLOGY

www.siv-isv.org

Virtual FOURTH CONGRESS

of the
Italian Society
for Virology

WEBINAR

FRIDAY, DECEMBER 11th, 2020

from 10.00 a.m. to 4.30 p.m.

RATIONALE

The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 virus and the COVID-19 disease were unknown before the outbreak began in Wuhan, China, in December 2019. The outbreak rapidly evolved, affecting other parts of China and other countries worldwide. On 30 January 2020, WHO declared that the outbreak of coronavirus disease (COVID-19) constituted a Public Health Emergency of International Concern and 11 March 2020, the Director General of WHO declared the COVID-19 outbreak a pandemic. The long incubation period of this new virus, which is mostly asymptomatic yet contagious, is a key reason for its rapid spread across the world.

Currently, there is no worldwide-approved treatment for COVID-19. Therefore, the clinical and scientific communities have joint efforts to reduce the severe impact of the outbreak. Research on previous emerging infectious diseases have created valuable knowledge that is being exploited for drug repurposing and accelerated vaccine development. However, it is important to generate knowledge on SARS-CoV-2 mechanisms of infection and its impact on host immunity, to guide the design of COVID-19 specific therapeutics and vaccines suitable for mass immunization.

The SARS-CoV-2 is a new strain of coronavirus, and the scientific community is rapidly gaining tremendous knowledge about this virus. Understanding of individual and population-level immunity to SARS-CoV-2 remains incomplete and developing reliable serological assays to detect previous infection has been an intense focus of the global scientific effort. Prevention of SARS-CoV-2 new infections may be the most effective approach, not only to prevent COVID-19 but also to block the spreading of the virus worldwide. Since the end of 2019, large efforts on multiple strategies are being adopted for the SARS-CoV-2 vaccine development. The development of a COVID-19 vaccine suitable for mass immunization is urgent and companies and research institutes have already reported the development of more than 115 vaccine candidates. Reorientation of research at many academic and industrial institutions is also currently in place, taking advantage of already existing knowledge and experience in fighting previous infectious diseases that may bring new solutions to the COVID-19 pipeline.

Thus, the large amount of information generated and reported in the last months raises the need for a consensus analysis, which is the rationale of this meeting.

SCIENTIFIC COMMITTEE

Guido Antonelli

Full Professor of Microbiology and Clinical Microbiology,
Department of Molecular Medicine,
"Sapienza" University of Rome, Italy

Arnaldo Caruso

Full Professor of Microbiology and Virology,
University of Brescia Medical School,
Brescia, Italy

Massimo Clementi

Full Professor of Microbiology and Virology,
"Vita-Salute" San Raffaele University,
Milan, Italy

FACULTY

GUIDO ANTONELLI (Rome, Italy)
CANIO BUONAVOGLIA (Bari, Italy)
FRANCESCA CACCURI (Brescia, Italy)
MARIA ROSARIA CAPOBIANCHI (Rome, Italy)
ARNALDO CARUSO (Brescia, Italy)
FRANCESCO CASTELLI (Brescia, Italy)
ROBERTA CAVALLO (Turin, Italy)
MASSIMO CLEMENTI (Milan, Italy)
MASSIMILIANO GALDIERO (Napoli, Italy)
GIUSEPPE IPPOLITO (Rome, Italy)
GIORGIO PALÙ (Padua, Italy)
MAURO PISTELLO (Pisa, Italy)
GUIDO POLI (Milan, Italy)
GIUSEPPE PORTELLA (Napoli, Italy)
ROBERTA RIZZO (Ferrara, Italy)
GUIDO SILVESTRI (Atlanta, USA)
OMBRETTA TURRIZIANI (Rome, Italy)
DAVIDE ZELLA (Baltimore, USA)

DECEMBER, 11th • Scientific Program

1ST SESSION - Morning

Chairmen: **G. Antonelli** (Rome, Italy), **A. Caruso** (Brescia, Italy), **G. Portella** (Napoli, Italy)

- 10.00-10.10 Introduction
A. Caruso (Brescia, Italy)
- 10.10-10.30 Animal coronaviruses
C. Buonavoglia (Bari, Italy)
- 10.30-10.50 Origin and evolution of SARS-CoV-2
G. Palù (Padua, Italy)
- 10.50-11.10 SARS-CoV-2 pandemic: how the virus spread around the world
G. Ippolito (Rome, Italy)
- 11.10-11.30 Molecular correlates of SARS-CoV-2 infection
M. Clementi (Milan, Italy)
- 11.30-11.50 SARS-CoV-2 mutations and possible implications for pathogenesis
D. Zella (Baltimore, USA)
- 11.50-12.30 Discussion
- 12.30-13.30 Break

2nd SESSION - Afternoon

Chairmen: **R. Cavallo** (Turin, Italy), **M. Galdiero** (Napoli, Italy), **M. Pistello** (Pisa, Italy)

- 13.30-13.50 Evolving testing strategy in view of new tools and increased opportunities
M.R. Capobianchi (Rome, Italy)
- 13.50-14.10 Endothelial cell dysfunction: a major player in SARS-CoV-2 infection
F. Caccuri (Brescia, Italy)
- 14.10-14.30 COVID-19: a clue from innate immunity
R. Rizzo (Ferrara, Italy)
- 14.30-14.50 How the body reacts to SARS-CoV-2?
G. Poli (Milan, Italy)
- 14.50-15.10 The light and shadow of a vaccine against SARS-CoV-2
G. Silvestri (Atlanta, USA)
- 15.10-15.30 Antiviral therapy: updates and hopes
O. Turriziani (Rome, Italy)
- 15.30-15.50 Clinical management of patients with COVID-19
F. Castelli (Brescia, Italy)
- 15.50-16.20 Discussion
- 16.20-16.30 Conclusions
G. Antonelli (Rome, Italy), **A. Caruso** (Brescia, Italy),
M. Clementi (Milan, Italy)

GENERAL INFORMATIONS

DATE

FRIDAY, DECEMBER 11TH, 2020

From 10.00 a.m. to 4.30 p.m.

CONGRESS VENUE

Webinar Congress

<https://bit.ly/3kQ3Vgn>

ORGANIZING SECRETARIAT AND PROVIDER NR. 265



Nadirex International S.r.l.
Via Riviera, 39 - 27100 Pavia
Tel. +39.0382.525714
Fax. +39.0382.525736
gloria.molla@nadirex.com
www.nadirex.com

Nadirex International assumes all responsibility for the contents, quality, and ethical correctness of this ECM activity.

CME - Continuous Medical Education Id ECM: 265-308306 (Remote Learning)

Learning hours: 6

Educational goal: 32 - Special topics of the S.S.N. and / or S.S.R. urgent and / or overtime identified by the Commission national for continuing education and from autonomous regions / provinces to deal with specific health emergencies with acquisition of process notions

Special topic: Coronavirus infection 2019-nCov

CME credits: Nr. 10,8

RL (Remote Learning) product type:

Live courses on dedicated multimedia platform (Virtual Classroom, Webinar) - Synchronous RL

Addressees of the Congress

The Congress is addressed to the following figures:

- Physician (Interdisciplinary)
- Nurse
- Biologist
- Pharmacist (Interdisciplinary)
- Psychologist (Interdisciplinary)
- Chemist
- Veterinary (Interdisciplinary)
- Biomedical Laboratory Technician

Participants: 300

PARTICIPANT RESOURCES REQUIRED

Email address (for registration), recent and updated web browser, Internet connection, devices to enable use of learning contents (pc, smartphone or tablet) with speakers (or earphones), microphone (only if the course calls for verbal interaction between teachers and participants).

REGISTRATION METHOD

You can register free of charge online as follows:

- go to www.nadirex.com
- click EVENTS session
- click the chosen event
- click on-line registration

OR:

- directly on the website:
<https://bit.ly/3kQ3Vgn>

For further informations please contact the Organizing Secretariat.

LEARNING VERIFICATION METHOD

Online multiple-choice questionnaire with double randomization. To earn ECM credits for the event you must:

- attend 90% of the teaching activities; give correct answers to at least 75% of the questions on the questionnaire (a maximum of five attempts to pass the test are allowed, subject to repetition of content activities for each attempt);
- fill out the RL evaluation form and the Nadirex International questionnaire (quality and learning needs).

Attention: the questionnaire will be online for only 3 (three) days after the event has concluded.

ORGANIZING SECRETARIAT



Nadirex International S.r.l.
Via Riviera, 39 - 27100 Pavia
Tel. +39.0382.525714
Fax. +39.0382.525736
gloria.molla@nadirex.com
www.nadirex.com

